PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33411349-0 2021 CD44 enhances adriamycin resistance in chronic myelogenous leukaemia cells K562. Doxorubicin 14-24 CD44 molecule (Indian blood group) Homo sapiens 0-4 33738958-7 2021 Doxorubicin (DOX)-loaded TTP and CD44-specific hyaluronic acid (HA)-comodified NPs (DOX@TTP-HA) are designed as following drug-loaded NPs. Doxorubicin 84-87 CD44 molecule (Indian blood group) Homo sapiens 33-37 33862128-2 2021 Along with its excellent biocompatibility, the prepared HA-beta-CD exhibits not only exceptionally high loading capacity for the model drugs doxorubicin and Rhodamine B through the formation of inclusion complexes with the beta-CD component, but also the capability of targeted drug delivery to cancerous cells with a high level of expression of CD44 receptors, attributable to its HA component. Doxorubicin 141-152 CD44 molecule (Indian blood group) Homo sapiens 346-350 33411349-1 2021 INTRODUCTION: To investigate CD44 effects on the adriamycin-resistant in chronic myelogenous leukaemia cells K562, we explored the role of CD44 in the K562 cells migration and apoptosis. Doxorubicin 49-59 CD44 molecule (Indian blood group) Homo sapiens 29-33 33411349-3 2021 We constructed K562/CD44 cells by transfection of an EGFP-SV40-CD44 plasmid, and adriamycin-resistant ability was confirmed by detecting migration and apoptosis-related proteins and mRNA expression using Western blotting and Real-time PCR respectively. Doxorubicin 81-91 CD44 molecule (Indian blood group) Homo sapiens 20-24 33411349-7 2021 CONCLUSIONS: CD44 might be involved in adriamycin resistance via regulation of P-gp, MMP-2, MMP-9, and Bcl-2/Bax. Doxorubicin 39-49 CD44 molecule (Indian blood group) Homo sapiens 13-17 31086900-10 2019 Surprisingly, EPR and Dox combination significantly down-regulated the CD44 receptor expression which is the main contributing factor of tumor metastasis. Doxorubicin 22-25 CD44 molecule (Indian blood group) Homo sapiens 71-75 33206362-0 2020 siRNA-mediated silencing of CD44 delivered by Jet Pei enhanced Doxorubicin chemo sensitivity and altered miRNA expression in human breast cancer cell line (MDA-MB468). Doxorubicin 63-74 CD44 molecule (Indian blood group) Homo sapiens 28-32 33206362-3 2020 This study aims to evaluate the combination therapy of Jet Pei/CD44-specific-siRNA/doxorubicin in breast cancer MDA-MB468 cell line. Doxorubicin 83-94 CD44 molecule (Indian blood group) Homo sapiens 63-67 33206362-9 2020 Moreover, the combination therapy of CD44-specific-siRNA with doxorubicin can be a promising treatment for patients with breast cancer. Doxorubicin 62-73 CD44 molecule (Indian blood group) Homo sapiens 37-41 32328816-4 2020 METHODS: Doxorubicin resistant MDA-MB-231 cell line was developed and characterized for the expression of multidrug resistance-related genes, CD44/CD24 markers, inflammatory cytokines, and the expression of STAT 3, Notch-1, and beta-catenin targeted genes. Doxorubicin 9-20 CD44 molecule (Indian blood group) Homo sapiens 142-146 32384236-4 2020 We demonstrated that cRGD@dHA-c-DOX resulted in highly improved cellular uptake and cell death in MDA-MB-231 tumor cells (CD44 +, integrin alphavbeta3 +) compared to those in Huh7 tumor cells (CD44 -, integrin alphavbeta3 -). Doxorubicin 32-35 CD44 molecule (Indian blood group) Homo sapiens 122-126 32384236-4 2020 We demonstrated that cRGD@dHA-c-DOX resulted in highly improved cellular uptake and cell death in MDA-MB-231 tumor cells (CD44 +, integrin alphavbeta3 +) compared to those in Huh7 tumor cells (CD44 -, integrin alphavbeta3 -). Doxorubicin 32-35 CD44 molecule (Indian blood group) Homo sapiens 193-197 31746936-4 2019 The Que and Dox co-loaded HA/ZIF (HA/ZIF/DQ) showed preferable stability under physiological conditions, pH-responsive drug release in an acidic environment and preferential homing capacity to the CD44 receptor-overexpressed HepG2/ADR cells. Doxorubicin 12-15 CD44 molecule (Indian blood group) Homo sapiens 197-201 31763810-2 2019 Here, we developed CD44 and folate receptor (FR) dually targeted nanoparticulate doxorubicin (HA/FA-NP-DOX) based on a direct conjugate of two purely natural ligands, hyaluronic acid and folic acid (FA), for safe, highly specific and potent treatment of ovarian tumor in vivo. Doxorubicin 81-92 CD44 molecule (Indian blood group) Homo sapiens 19-23 31763810-2 2019 Here, we developed CD44 and folate receptor (FR) dually targeted nanoparticulate doxorubicin (HA/FA-NP-DOX) based on a direct conjugate of two purely natural ligands, hyaluronic acid and folic acid (FA), for safe, highly specific and potent treatment of ovarian tumor in vivo. Doxorubicin 103-106 CD44 molecule (Indian blood group) Homo sapiens 19-23 31763810-5 2019 Cellular studies corroborated that HA/FA-NP-DOX possessed high selectivity to both CD44 and FR, resulting in strong killing of CD44 and FR positive SKOV-3 ovarian cancer cells while low toxicity against CD44 and FR negative L929 fibroblast cells. Doxorubicin 44-47 CD44 molecule (Indian blood group) Homo sapiens 83-87 31763810-5 2019 Cellular studies corroborated that HA/FA-NP-DOX possessed high selectivity to both CD44 and FR, resulting in strong killing of CD44 and FR positive SKOV-3 ovarian cancer cells while low toxicity against CD44 and FR negative L929 fibroblast cells. Doxorubicin 44-47 CD44 molecule (Indian blood group) Homo sapiens 127-131 31763810-5 2019 Cellular studies corroborated that HA/FA-NP-DOX possessed high selectivity to both CD44 and FR, resulting in strong killing of CD44 and FR positive SKOV-3 ovarian cancer cells while low toxicity against CD44 and FR negative L929 fibroblast cells. Doxorubicin 44-47 CD44 molecule (Indian blood group) Homo sapiens 127-131 31623608-7 2019 In drug-resistant human breast cancer MCF-7/ADR cells, HPPDC nanoparticles significantly enhanced the cellular uptake of DOX through the endocytosis mediated by CD44/HA specific binding and the down-regulated P-gp expression induced by COX-2 inhibition, and thus notably increased the cytotoxicity and apoptosis-inducing activity of DOX. Doxorubicin 121-124 CD44 molecule (Indian blood group) Homo sapiens 161-165 32849878-2 2020 Based on the expression of CD44 and CD133, two well-recognized cell surface markers for CSC identification, we tried to separate HCT8 colorectal cancer cells into different subpopulations and then investigated how the expression of CD44 and CD133 associated with doxorubicin (DXR) resistance. Doxorubicin 263-274 CD44 molecule (Indian blood group) Homo sapiens 232-236 32849878-3 2020 Interestingly, DXR resistance was observed in CD44+CD133+ (P < 0.01vs. Doxorubicin 15-18 CD44 molecule (Indian blood group) Homo sapiens 46-50 32760666-0 2020 Enrichment of CD44 in Exosomes From Breast Cancer Cells Treated With Doxorubicin Promotes Chemoresistance. Doxorubicin 69-80 CD44 molecule (Indian blood group) Homo sapiens 14-18 32760666-4 2020 The expression of the candidate target exosomic CD44 in DOX-resistant cells (A/Exo) was higher than in parental breast cancer cells (S/Exo), and the increasing levels of exosomic CD44 (21.65-fold) were higher than those of cellular CD44 (6.55-fold) (all p < 0.05). Doxorubicin 56-59 CD44 molecule (Indian blood group) Homo sapiens 48-52 32760666-4 2020 The expression of the candidate target exosomic CD44 in DOX-resistant cells (A/Exo) was higher than in parental breast cancer cells (S/Exo), and the increasing levels of exosomic CD44 (21.65-fold) were higher than those of cellular CD44 (6.55-fold) (all p < 0.05). Doxorubicin 56-59 CD44 molecule (Indian blood group) Homo sapiens 179-183 32760666-4 2020 The expression of the candidate target exosomic CD44 in DOX-resistant cells (A/Exo) was higher than in parental breast cancer cells (S/Exo), and the increasing levels of exosomic CD44 (21.65-fold) were higher than those of cellular CD44 (6.55-fold) (all p < 0.05). Doxorubicin 56-59 CD44 molecule (Indian blood group) Homo sapiens 179-183 32104479-5 2019 It was interesting to found that both the HA-CD44 binding affinity and induced CD44 clustering by HA-based NPs were HA MW-dependent, the two of which determine the apparent targeting efficacy of Dox/HCV NPs in the conflicting directions. Doxorubicin 195-198 CD44 molecule (Indian blood group) Homo sapiens 45-49 32104479-5 2019 It was interesting to found that both the HA-CD44 binding affinity and induced CD44 clustering by HA-based NPs were HA MW-dependent, the two of which determine the apparent targeting efficacy of Dox/HCV NPs in the conflicting directions. Doxorubicin 195-198 CD44 molecule (Indian blood group) Homo sapiens 79-83 31460017-5 2019 A GO-HA-Dox/Ptx system was significantly better than the GO-Dox/Ptx system at specifically killing CD44-expressing MDA-MB-231 cells but not BT-474 cells that do not express CD44. Doxorubicin 8-11 CD44 molecule (Indian blood group) Homo sapiens 99-103 30879657-0 2019 Preparation, characterisation and in vitro and in vivo evaluation of CD44-targeted chondroitin sulphate-conjugated doxorubicin PLGA nanoparticles. Doxorubicin 115-126 CD44 molecule (Indian blood group) Homo sapiens 69-73 30879657-3 2019 Taking advantage of the enhanced permeability and CD44-mediated endocytosis, CS-Dox-PLGA showed excellent capacity for penetrating the peripheral tumour barrier and into the nucleus of tumour cells. Doxorubicin 80-83 CD44 molecule (Indian blood group) Homo sapiens 50-54 31460017-5 2019 A GO-HA-Dox/Ptx system was significantly better than the GO-Dox/Ptx system at specifically killing CD44-expressing MDA-MB-231 cells but not BT-474 cells that do not express CD44. Doxorubicin 8-11 CD44 molecule (Indian blood group) Homo sapiens 173-177 31460017-5 2019 A GO-HA-Dox/Ptx system was significantly better than the GO-Dox/Ptx system at specifically killing CD44-expressing MDA-MB-231 cells but not BT-474 cells that do not express CD44. Doxorubicin 60-63 CD44 molecule (Indian blood group) Homo sapiens 99-103 30782256-6 2019 The SWCNTs-DOX-HA showed a significantly improved intracellular delivery of DOX in CD44 overexpressing MDA-MB-231 cells by flow cytometry and confocal microscopy. Doxorubicin 11-14 CD44 molecule (Indian blood group) Homo sapiens 83-87 30782256-6 2019 The SWCNTs-DOX-HA showed a significantly improved intracellular delivery of DOX in CD44 overexpressing MDA-MB-231 cells by flow cytometry and confocal microscopy. Doxorubicin 76-79 CD44 molecule (Indian blood group) Homo sapiens 83-87 29352988-5 2018 Among the upregulated genes, MAPK3, PRKCZ and STAT3, STAT3 presented a higher level of upregulation in the DOX-treated CD44+/high/CD24-/low/ALDH+ BCSCs-like subset. Doxorubicin 107-110 CD44 molecule (Indian blood group) Homo sapiens 119-123 30960121-3 2019 In vitro cell viability assay proved that LM-HA had good biocompatibility, and drug-loaded LM-HA/DOX exhibited targeted anti-tumor effects against HeLa cells with CD44 receptors overexpressed. Doxorubicin 97-100 CD44 molecule (Indian blood group) Homo sapiens 163-167 30960121-4 2019 In addition, the flow cytometric detection and confocal laser scanning microscope results confirmed that LM-HA/DOX could be specifically internalized by HeLa cells via CD44-mediated endocytosis. Doxorubicin 111-114 CD44 molecule (Indian blood group) Homo sapiens 168-172 30396468-0 2018 The CD44 variant induces K562 cell acquired with resistance to adriamycin via NF-kappaB/Snail/Bcl-2 pathway. Doxorubicin 63-73 CD44 molecule (Indian blood group) Homo sapiens 4-8 29969665-5 2018 We synthesized CD44-targeted DOX loaded nanoparticles (PSHA-DOXNPs) and evaluated their anticancer efficacy in combination with curcumin loaded selenium nanoparticles (Se-Cur NPs), previously developed by our group (Kumari et al., 2017). Doxorubicin 29-32 CD44 molecule (Indian blood group) Homo sapiens 15-19 30100720-0 2018 Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery. Doxorubicin 83-94 CD44 molecule (Indian blood group) Homo sapiens 20-24 30100720-1 2018 Introduction: A reduction-sensitive CD44-positive tumor-targetable drug delivery system for doxorubicin (DOX) delivery was developed based on hyaluronic acid (HA)-grafted polymers. Doxorubicin 92-103 CD44 molecule (Indian blood group) Homo sapiens 36-40 30100720-1 2018 Introduction: A reduction-sensitive CD44-positive tumor-targetable drug delivery system for doxorubicin (DOX) delivery was developed based on hyaluronic acid (HA)-grafted polymers. Doxorubicin 105-108 CD44 molecule (Indian blood group) Homo sapiens 36-40 29357289-7 2018 Further studies showed that the HA-fabricated particles could achieve much enhanced cellular uptake via CD44 receptor-mediated endocytosis by Hela cells (CD44 receptor-positive), and as a result, doxorubicin-loaded MSNs exhibited significantly enhanced drug efficacy toward cancer cells overexpressing CD44 receptor (IC50 = 0.56 mug/mL), whereas the normal cells showed weakly cytotoxicity (IC50 = 1.03 mug/mL). Doxorubicin 196-207 CD44 molecule (Indian blood group) Homo sapiens 104-108 29357289-7 2018 Further studies showed that the HA-fabricated particles could achieve much enhanced cellular uptake via CD44 receptor-mediated endocytosis by Hela cells (CD44 receptor-positive), and as a result, doxorubicin-loaded MSNs exhibited significantly enhanced drug efficacy toward cancer cells overexpressing CD44 receptor (IC50 = 0.56 mug/mL), whereas the normal cells showed weakly cytotoxicity (IC50 = 1.03 mug/mL). Doxorubicin 196-207 CD44 molecule (Indian blood group) Homo sapiens 154-158 29357289-7 2018 Further studies showed that the HA-fabricated particles could achieve much enhanced cellular uptake via CD44 receptor-mediated endocytosis by Hela cells (CD44 receptor-positive), and as a result, doxorubicin-loaded MSNs exhibited significantly enhanced drug efficacy toward cancer cells overexpressing CD44 receptor (IC50 = 0.56 mug/mL), whereas the normal cells showed weakly cytotoxicity (IC50 = 1.03 mug/mL). Doxorubicin 196-207 CD44 molecule (Indian blood group) Homo sapiens 154-158 29495404-0 2018 Targeting Glioblastoma Cells Expressing CD44 with Liposomes Encapsulating Doxorubicin and Displaying Chlorotoxin-IgG Fc Fusion Protein. Doxorubicin 74-85 CD44 molecule (Indian blood group) Homo sapiens 40-44 30960117-5 2019 Significantly, the DOX-loaded nanocomposite (DOX@CDHA-MGO) has displayed CD44 receptor-mediated active targeting recognition and chemo-photothermal synergistic therapy of hepatoma cells. Doxorubicin 19-22 CD44 molecule (Indian blood group) Homo sapiens 73-77 30960117-5 2019 Significantly, the DOX-loaded nanocomposite (DOX@CDHA-MGO) has displayed CD44 receptor-mediated active targeting recognition and chemo-photothermal synergistic therapy of hepatoma cells. Doxorubicin 45-48 CD44 molecule (Indian blood group) Homo sapiens 73-77 30201431-5 2018 HA/DOX-MTNst markedly improved the cellular uptake of DOX in an apparently CD44 receptor-dependent manner, and increased the number of apoptotic cells as compared to free DOX. Doxorubicin 3-6 CD44 molecule (Indian blood group) Homo sapiens 75-79 30201431-5 2018 HA/DOX-MTNst markedly improved the cellular uptake of DOX in an apparently CD44 receptor-dependent manner, and increased the number of apoptotic cells as compared to free DOX. Doxorubicin 54-57 CD44 molecule (Indian blood group) Homo sapiens 75-79 30201431-5 2018 HA/DOX-MTNst markedly improved the cellular uptake of DOX in an apparently CD44 receptor-dependent manner, and increased the number of apoptotic cells as compared to free DOX. Doxorubicin 54-57 CD44 molecule (Indian blood group) Homo sapiens 75-79 29352988-7 2018 STAT3 was highlighted as a molecular signature in the CD44+/high/CD24-/low/ALDH1+ BCSCs-like subset obtained from the TNBC BT-549 cell line related to DOX resistance. Doxorubicin 151-154 CD44 molecule (Indian blood group) Homo sapiens 54-58 29371972-10 2017 Additionally, attenuation of CD44 expression sensitized these cell models against osteosarcoma chemotherapy with doxorubicin but not methotrexate and cisplatin. Doxorubicin 113-124 CD44 molecule (Indian blood group) Homo sapiens 29-33 29107218-3 2018 All doxorubicin (Dox)-resistant tumors expressed higher levels of cancer stem-like cell biomarkers, including CD44, Wnt and its receptor LRP5/6, relative to Dox-sensitive tumors. Doxorubicin 4-15 CD44 molecule (Indian blood group) Homo sapiens 110-114 29107218-3 2018 All doxorubicin (Dox)-resistant tumors expressed higher levels of cancer stem-like cell biomarkers, including CD44, Wnt and its receptor LRP5/6, relative to Dox-sensitive tumors. Doxorubicin 17-20 CD44 molecule (Indian blood group) Homo sapiens 110-114 30371105-7 2018 Importantly, the accumulation of DOX-loaded HNPs was largely increased due to the targeted reorganization of CD44 or LYCE-1 receptors by HA moieties on the surface of HNPs. Doxorubicin 33-36 CD44 molecule (Indian blood group) Homo sapiens 109-113 28743090-0 2017 NIR and UV-responsive degradable hyaluronic acid nanogels for CD44-targeted and remotely triggered intracellular doxorubicin delivery. Doxorubicin 113-124 CD44 molecule (Indian blood group) Homo sapiens 62-66 31251139-2 2017 Thus, in the present study, a novel macromolecular prodrug conjugates was designed and developed, which can target CD44-overexpressed tumor cells in addition to releasing doxorubicin (Dox) that is passively triggered by the acidic microenvironment of tumor cells. Doxorubicin 171-182 CD44 molecule (Indian blood group) Homo sapiens 115-119 31251139-2 2017 Thus, in the present study, a novel macromolecular prodrug conjugates was designed and developed, which can target CD44-overexpressed tumor cells in addition to releasing doxorubicin (Dox) that is passively triggered by the acidic microenvironment of tumor cells. Doxorubicin 184-187 CD44 molecule (Indian blood group) Homo sapiens 115-119 28887972-5 2017 Cellular uptake experiment results indicated that DOX-GNRs@mSiO2-HA-RGD can be dual-targeted to ovarian cancer cells via CD44 and integrin receptor mediated endocytosis pathway. Doxorubicin 50-53 CD44 molecule (Indian blood group) Homo sapiens 121-125 30023561-0 2017 Five-Part Pentameric Nanocomplex Shows Improved Efficacy of Doxorubicin in CD44+ Cancer Cells. Doxorubicin 60-71 CD44 molecule (Indian blood group) Homo sapiens 75-79 30023561-6 2017 The PNC is almost an order of magnitude more effective than Dox alone in CD44+ cells versus CD44 low cells. Doxorubicin 60-63 CD44 molecule (Indian blood group) Homo sapiens 73-77 28743090-2 2017 Here, we developed NIR and UV-responsive degradable nanogels from hyaluronic acid-g-7-N,N-diethylamino-4-hydroxymethylcoumarin (HA-CM) for CD44 targeted and remotely controlled intracellular doxorubicin (DOX) delivery. Doxorubicin 191-202 CD44 molecule (Indian blood group) Homo sapiens 139-143 28743090-2 2017 Here, we developed NIR and UV-responsive degradable nanogels from hyaluronic acid-g-7-N,N-diethylamino-4-hydroxymethylcoumarin (HA-CM) for CD44 targeted and remotely controlled intracellular doxorubicin (DOX) delivery. Doxorubicin 204-207 CD44 molecule (Indian blood group) Homo sapiens 139-143 28743090-4 2017 MTT assays showed that DOX-loaded HA-CM nanogels combined with NIR irradiation induced much higher antitumor activity to MCF-7 cells (CD44+) than to U-87MG cells (CD44-) and free HA pretreated MCF-7 cells. Doxorubicin 23-26 CD44 molecule (Indian blood group) Homo sapiens 134-138 28743090-4 2017 MTT assays showed that DOX-loaded HA-CM nanogels combined with NIR irradiation induced much higher antitumor activity to MCF-7 cells (CD44+) than to U-87MG cells (CD44-) and free HA pretreated MCF-7 cells. Doxorubicin 23-26 CD44 molecule (Indian blood group) Homo sapiens 163-167 28743090-5 2017 CLSM observations confirmed that DOX-loaded HA-CM nanogels were internalized by CD44+ cells via receptor mediated endocytosis mechanism, and intracellular DOX release was triggered by NIR. Doxorubicin 33-36 CD44 molecule (Indian blood group) Homo sapiens 80-84 28819559-11 2017 The triple negative carcinoma-derived Doxorubicin-resistant phenotype exhibited cancer stem cell markers, including tumor spheroid formation and expression of CD44, NANOG and c-Myc. Doxorubicin 38-49 CD44 molecule (Indian blood group) Homo sapiens 159-163 33465938-8 2017 Therefore, the developed LAP-PLA-PEG-PEI-(Au0)50-HA/DOX nanocomplexes can be used as a promising theranostic platform for targeted imaging and chemotherapy of CD44-overexpressed tumors. Doxorubicin 52-55 CD44 molecule (Indian blood group) Homo sapiens 159-163 28576067-7 2017 Cellular uptake experiments and confocal images demonstrated that pH-sensitive DOX/HOD micelles could be internalized efficiently by CD44 receptor mediated endocytosis, and then DOX was rapidly released due to pH-induced degradable of OD to cell nucleus compared to the non-sensitive micelles. Doxorubicin 79-82 CD44 molecule (Indian blood group) Homo sapiens 133-137 28422250-2 2017 Herein, we synthesized a novel doxorubicin (DOX)-entrapped mesoporous silica nanoparticle (MSN), covalently-conjugated with two aptamers, for simultaneously targeting EpCAM and CD44, the typical surface biomarkers of colorectal CTCs. Doxorubicin 31-42 CD44 molecule (Indian blood group) Homo sapiens 177-181 28422250-2 2017 Herein, we synthesized a novel doxorubicin (DOX)-entrapped mesoporous silica nanoparticle (MSN), covalently-conjugated with two aptamers, for simultaneously targeting EpCAM and CD44, the typical surface biomarkers of colorectal CTCs. Doxorubicin 44-47 CD44 molecule (Indian blood group) Homo sapiens 177-181 27742685-6 2016 Uptake by cancer cells was mediated efficiently by CD44 receptor-mediated endocytosis and the MSN exhibited good biocompatibility in vitro and in vivo MSN-HA/Dox nanoparticles induced apoptosis in cancer cells more efficiently than free doxorubicin and inhibited tumor growth with minimal systemic toxicity in vivo Collectively, our findings offered a preclinical proof of concept for a novel targeted drug delivery carrier system for cancer therapy. Doxorubicin 158-161 CD44 molecule (Indian blood group) Homo sapiens 51-55 27913127-6 2017 Moreover, (DOX+Cur)-PMs more efficiently internalized into cancer cells and enhanced the cellular uptake of DOX via energy-dependent and caveolae-mediated endocytosis, and significantly reversed MDR effects via CD44 targeting delivery and the synergic effect of released Cur. Doxorubicin 11-14 CD44 molecule (Indian blood group) Homo sapiens 211-215 27616692-9 2016 Cell uptake studies indicated that GO-SA could specifically transport the DOX into Hela cells over-expressing CD44 receptors and showed enhanced toxicity. Doxorubicin 74-77 CD44 molecule (Indian blood group) Homo sapiens 110-114 26784587-9 2016 DISCUSSION: DOX was efficiently delivered to the tumor site by active targeting via HA and CD44 receptor interaction. Doxorubicin 12-15 CD44 molecule (Indian blood group) Homo sapiens 91-95 27853369-6 2016 Specifically, HA-VES/DOX decreased the activity of CD44 mRNA and improved the targeting efficiency on MCF-7 cells, based on the active recognition between HA and CD44 receptor. Doxorubicin 21-24 CD44 molecule (Indian blood group) Homo sapiens 51-55 27853369-6 2016 Specifically, HA-VES/DOX decreased the activity of CD44 mRNA and improved the targeting efficiency on MCF-7 cells, based on the active recognition between HA and CD44 receptor. Doxorubicin 21-24 CD44 molecule (Indian blood group) Homo sapiens 162-166 27120809-7 2016 Furthermore, CD44 driven HALNP uptake into GBM cells resulted in lysosomal evasion and increased efficacy of Doxorubicin, a model anti-neoplastic agent, while the astrocytes and microglia cells exhibited extensive HALNP-lysosome co-localization and decreased antineoplastic potency. Doxorubicin 109-120 CD44 molecule (Indian blood group) Homo sapiens 13-17 27576338-10 2016 Doxorubicin-loaded multifunctional nanoparticles based on hyaluronic acid-g-poly(gamma-benzyl-l-glutamate)-lipoic acid conjugates exhibit a high drug loading, superior stability, fast bioresponsivity, high tolerability, and obvious selectivity toward CD44-overexpressing tumors in vivo. Doxorubicin 0-11 CD44 molecule (Indian blood group) Homo sapiens 251-255 27560126-5 2016 Nanoparticles with HA as the final layer (Dox Ab HA) showed maximum cellular uptake in MDA-MB-231 cells owing to the CD44 receptor-mediated endocytosis and hence, exhibited more cytotoxicity as compared to free Dox. Doxorubicin 42-45 CD44 molecule (Indian blood group) Homo sapiens 117-121 27107383-5 2016 MSNs/SS/HA@DOX exhibited higher cellular uptake efficacy via CD44-mediated endocytosis by HeLa cells (CD44 over-expressed cells) than by LO2 cells (CD44 deficient cells). Doxorubicin 11-14 CD44 molecule (Indian blood group) Homo sapiens 61-65 27107383-5 2016 MSNs/SS/HA@DOX exhibited higher cellular uptake efficacy via CD44-mediated endocytosis by HeLa cells (CD44 over-expressed cells) than by LO2 cells (CD44 deficient cells). Doxorubicin 11-14 CD44 molecule (Indian blood group) Homo sapiens 102-106 27107383-5 2016 MSNs/SS/HA@DOX exhibited higher cellular uptake efficacy via CD44-mediated endocytosis by HeLa cells (CD44 over-expressed cells) than by LO2 cells (CD44 deficient cells). Doxorubicin 11-14 CD44 molecule (Indian blood group) Homo sapiens 102-106 27249228-5 2016 Loading an anticancer drug (i.e., doxorubicin) into the obtained capsules resulted in significantly higher cytotoxicity to CD44+ cells but lower cytotoxicity to CD44- cells. Doxorubicin 34-45 CD44 molecule (Indian blood group) Homo sapiens 123-127 27249228-5 2016 Loading an anticancer drug (i.e., doxorubicin) into the obtained capsules resulted in significantly higher cytotoxicity to CD44+ cells but lower cytotoxicity to CD44- cells. Doxorubicin 34-45 CD44 molecule (Indian blood group) Homo sapiens 161-165 26276718-4 2015 Further, CD44(+)/Musashi-1(+) cells exhibited high drug efflux bump activity and were resistant to doxorubicin (Dox)-induced apoptosis, and unregulated the ATP-binding cassette sub-family G member 2 (ABCG2) expression,. Doxorubicin 99-110 CD44 molecule (Indian blood group) Homo sapiens 9-13 26853764-0 2016 CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release. Doxorubicin 87-98 CD44 molecule (Indian blood group) Homo sapiens 0-4 26853764-1 2016 UNLABELLED: CD44-specific and redox-responsive nanoparticles were prepared by coating a bioreducible chitosan-based nanoparticles with hyaluronic acid for intracellular glutathione-triggered reactive oxygen species (ROS) production and doxorubicin (DOX) release. Doxorubicin 236-247 CD44 molecule (Indian blood group) Homo sapiens 12-16 26853764-1 2016 UNLABELLED: CD44-specific and redox-responsive nanoparticles were prepared by coating a bioreducible chitosan-based nanoparticles with hyaluronic acid for intracellular glutathione-triggered reactive oxygen species (ROS) production and doxorubicin (DOX) release. Doxorubicin 249-252 CD44 molecule (Indian blood group) Homo sapiens 12-16 26853764-8 2016 Confocal fluorescence microscopy demonstrated that the Cu(II)-DOX-loaded NPs effectively delivered DOX to human colon adenocarcinoma cells (HT-29) by active targeting via HA-CD44 interactions. Doxorubicin 62-65 CD44 molecule (Indian blood group) Homo sapiens 174-178 26853764-8 2016 Confocal fluorescence microscopy demonstrated that the Cu(II)-DOX-loaded NPs effectively delivered DOX to human colon adenocarcinoma cells (HT-29) by active targeting via HA-CD44 interactions. Doxorubicin 99-102 CD44 molecule (Indian blood group) Homo sapiens 174-178 26853764-10 2016 In vitro cytotoxicity assays revealed that Cu(II)-DOX-loaded NPs sensitized cells to DOX-induced cytotoxicity in CD44-overexpressing HT-29 cells compared to CD44 low-expressing HCT-15 cells. Doxorubicin 50-53 CD44 molecule (Indian blood group) Homo sapiens 113-117 26853764-10 2016 In vitro cytotoxicity assays revealed that Cu(II)-DOX-loaded NPs sensitized cells to DOX-induced cytotoxicity in CD44-overexpressing HT-29 cells compared to CD44 low-expressing HCT-15 cells. Doxorubicin 50-53 CD44 molecule (Indian blood group) Homo sapiens 157-161 26853764-10 2016 In vitro cytotoxicity assays revealed that Cu(II)-DOX-loaded NPs sensitized cells to DOX-induced cytotoxicity in CD44-overexpressing HT-29 cells compared to CD44 low-expressing HCT-15 cells. Doxorubicin 85-88 CD44 molecule (Indian blood group) Homo sapiens 113-117 26853764-13 2016 The Cu(II)-DOX-loaded nanoparticle sensitized cells to DOX-induced cytotoxicity in CD44-overexpressing HT-29 cells. Doxorubicin 11-14 CD44 molecule (Indian blood group) Homo sapiens 83-87 26853764-13 2016 The Cu(II)-DOX-loaded nanoparticle sensitized cells to DOX-induced cytotoxicity in CD44-overexpressing HT-29 cells. Doxorubicin 55-58 CD44 molecule (Indian blood group) Homo sapiens 83-87 26453853-5 2016 Cell uptake studies show that the GO-CMC-FI-HA/DOX complex can specifically target cancer cells, which are over-expressing CD44 receptors and effectively inhibit their growth. Doxorubicin 47-50 CD44 molecule (Indian blood group) Homo sapiens 123-127 26546432-6 2016 Following sorting of CD44(+)CD24(-) cells from spheres, we showed that CD44(+)CD24(-) cells displayed stem cell-like features and were resistant to chemotherapy drug doxorubicin. Doxorubicin 166-177 CD44 molecule (Indian blood group) Homo sapiens 21-25 26546432-6 2016 Following sorting of CD44(+)CD24(-) cells from spheres, we showed that CD44(+)CD24(-) cells displayed stem cell-like features and were resistant to chemotherapy drug doxorubicin. Doxorubicin 166-177 CD44 molecule (Indian blood group) Homo sapiens 71-75 26276718-4 2015 Further, CD44(+)/Musashi-1(+) cells exhibited high drug efflux bump activity and were resistant to doxorubicin (Dox)-induced apoptosis, and unregulated the ATP-binding cassette sub-family G member 2 (ABCG2) expression,. Doxorubicin 112-115 CD44 molecule (Indian blood group) Homo sapiens 9-13 26149228-5 2015 The cellular uptake of DOX from the CSA-DOCA NPs in CD44 receptor-positive human breast adenocarcinoma MDA-MB-231 cells was reduced when co-treated with free CSA, indicating the interaction between CSA and the CD44 receptor. Doxorubicin 23-26 CD44 molecule (Indian blood group) Homo sapiens 52-56 26331442-6 2015 After the PFEP/HA-Dox complex was exposed to HAase or was taken up by cancer cells through the specific binding between HA and CD44 receptor, HA was degraded by HAase to release the Dox, leading to the recovery of PFEP fluorescence to the "turn-on" state. Doxorubicin 18-21 CD44 molecule (Indian blood group) Homo sapiens 127-131 26331442-6 2015 After the PFEP/HA-Dox complex was exposed to HAase or was taken up by cancer cells through the specific binding between HA and CD44 receptor, HA was degraded by HAase to release the Dox, leading to the recovery of PFEP fluorescence to the "turn-on" state. Doxorubicin 182-185 CD44 molecule (Indian blood group) Homo sapiens 127-131 26149228-5 2015 The cellular uptake of DOX from the CSA-DOCA NPs in CD44 receptor-positive human breast adenocarcinoma MDA-MB-231 cells was reduced when co-treated with free CSA, indicating the interaction between CSA and the CD44 receptor. Doxorubicin 23-26 CD44 molecule (Indian blood group) Homo sapiens 210-214 25596560-0 2015 Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. Doxorubicin 102-113 CD44 molecule (Indian blood group) Homo sapiens 132-136 26004286-2 2015 We developed a doxorubicin-encapsulated polymeric nanoparticle surface-decorated with chitosan that can specifically target the CD44 receptors of these cells. Doxorubicin 15-26 CD44 molecule (Indian blood group) Homo sapiens 128-132 26004286-4 2015 This nanoparticle design strategy increases the cytotoxicity of the doxorubicin by six times in comparison to the use of free doxorubicin for eliminating CD44(+) cancer stem-like cells residing in 3D mammary tumor spheroids (i.e., mammospheres). Doxorubicin 68-79 CD44 molecule (Indian blood group) Homo sapiens 154-158 26004286-4 2015 This nanoparticle design strategy increases the cytotoxicity of the doxorubicin by six times in comparison to the use of free doxorubicin for eliminating CD44(+) cancer stem-like cells residing in 3D mammary tumor spheroids (i.e., mammospheres). Doxorubicin 126-137 CD44 molecule (Indian blood group) Homo sapiens 154-158 25929763-0 2015 Retraction Note to: Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin. Doxorubicin 117-128 CD44 molecule (Indian blood group) Homo sapiens 43-47 25898852-4 2015 With a double emulsion method, a nano delivery system was constructed to deliver doxorubicin (DOX) and cyclopamine (CYC, a primary inhibitor of the hedgehog signaling pathway of CSCs) to both a CD44-overexpressing breast CSC subpopulation and bulk breast cancer cells and allow an on-demand release. Doxorubicin 81-92 CD44 molecule (Indian blood group) Homo sapiens 194-198 25898852-4 2015 With a double emulsion method, a nano delivery system was constructed to deliver doxorubicin (DOX) and cyclopamine (CYC, a primary inhibitor of the hedgehog signaling pathway of CSCs) to both a CD44-overexpressing breast CSC subpopulation and bulk breast cancer cells and allow an on-demand release. Doxorubicin 94-97 CD44 molecule (Indian blood group) Homo sapiens 194-198 25596560-5 2015 Notably, MTT assays showed that DOX-loaded crosslinked HA-Lys-LA10 nanoparticles possessed an apparent targetability and a superior antitumor activity toward CD44 receptor overexpressing DOX-resistant MCF-7 human breast cancer cells (MCF-7/ADR). Doxorubicin 32-35 CD44 molecule (Indian blood group) Homo sapiens 158-162 25596560-5 2015 Notably, MTT assays showed that DOX-loaded crosslinked HA-Lys-LA10 nanoparticles possessed an apparent targetability and a superior antitumor activity toward CD44 receptor overexpressing DOX-resistant MCF-7 human breast cancer cells (MCF-7/ADR). Doxorubicin 187-190 CD44 molecule (Indian blood group) Homo sapiens 158-162 26117979-5 2015 Overexpression of CD44, observed in many ovarian cancer cells, is used in creating carriers for selective delivery of various drugs (paclitaxel, doxorubicin, camptothecin or cisplatin) to cancer cells. Doxorubicin 145-156 CD44 molecule (Indian blood group) Homo sapiens 18-22 24365705-5 2014 However, MTT assay against Michigan Cancer Foundation-7 (MCF-7) cells (overexpressed CD44 receptors) showed that DOX-loaded micelles with a low PHis DS were highly cytotoxic. Doxorubicin 113-116 CD44 molecule (Indian blood group) Homo sapiens 85-89 25242358-1 2014 The in vitro efficacy and selectivity of Hyaluronan-Doxorubicin complexes to affect the viability of overexpressing CD44 receptor cells. Doxorubicin 52-63 CD44 molecule (Indian blood group) Homo sapiens 116-120 24715151-0 2014 Doxorubicin induces drug resistance and expression of the novel CD44st via NF-kappaB in human breast cancer MCF-7 cells. Doxorubicin 0-11 CD44 molecule (Indian blood group) Homo sapiens 64-68 25449802-0 2015 Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation. Doxorubicin 72-83 CD44 molecule (Indian blood group) Homo sapiens 8-12 23589132-0 2013 Response of CD44+/CD24-/low breast cancer stem/progenitor cells to tamoxifen- and doxorubicin-induced autophagy. Doxorubicin 82-93 CD44 molecule (Indian blood group) Homo sapiens 12-16 24130147-3 2014 It is discovered that stable amide coupling of doxorubicin (DOX) tohyaluronan (HA) shows dose dependent cytotoxicity to CD44 positive human coloncancer cells (HCT116) as compared to human breast cancer cells(MCF-7) and mouse fibroblast cells (NIH-3T3), which express less CD44 receptor. Doxorubicin 47-58 CD44 molecule (Indian blood group) Homo sapiens 120-124 24130147-3 2014 It is discovered that stable amide coupling of doxorubicin (DOX) tohyaluronan (HA) shows dose dependent cytotoxicity to CD44 positive human coloncancer cells (HCT116) as compared to human breast cancer cells(MCF-7) and mouse fibroblast cells (NIH-3T3), which express less CD44 receptor. Doxorubicin 60-63 CD44 molecule (Indian blood group) Homo sapiens 120-124 32261192-4 2013 With its targeted and stimulated delivery of aromatic drugs to the target cells, DOX-loaded piHNC (piHNC/DOX) provided effectual therapeutic activity in both in vitro and in vivo models of CD44-positive human gastric cancer, which is suitable as a facile and efficient drug delivery platform. Doxorubicin 81-84 CD44 molecule (Indian blood group) Homo sapiens 189-193 32261192-4 2013 With its targeted and stimulated delivery of aromatic drugs to the target cells, DOX-loaded piHNC (piHNC/DOX) provided effectual therapeutic activity in both in vitro and in vivo models of CD44-positive human gastric cancer, which is suitable as a facile and efficient drug delivery platform. Doxorubicin 105-108 CD44 molecule (Indian blood group) Homo sapiens 189-193 23974104-7 2013 Disulfiram and doxorubicin cooperated to induce cell death as well as cellular senescence, and targeted the ESA(+)/CD24(-/low)/CD44(+) cancer stem cell population. Doxorubicin 15-26 CD44 molecule (Indian blood group) Homo sapiens 127-131 23589132-5 2013 For this purpose, the CD44+/CD24-/low MCF-7 breast cancer stem/progenitor cell population was isolated and treated with doxorubicin or tamoxifen and evaluated for their response to growth, autophagy and apoptosis. Doxorubicin 120-131 CD44 molecule (Indian blood group) Homo sapiens 22-26 23589132-6 2013 Our findings suggest that CD44+/CD24-/low cells were less sensitive to doxorubicin, but did not demonstrate a significant difference towards tamoxifen in regards to the induction of autophagy. Doxorubicin 71-82 CD44 molecule (Indian blood group) Homo sapiens 26-30 23554768-7 2012 The CD44(+)CD24(-/low) subpopulation was also upregulated in TAM-R cells with less sensitivity to adriamycin than MCF-7. Doxorubicin 98-108 CD44 molecule (Indian blood group) Homo sapiens 4-8 23529646-5 2013 To validate our hypothesis, in the first of two articles, we report the synthesis of doxorubicin (DOX)-loaded, hyaluronan (HA) coated silica nanoparticles (SNPs) containing a highly fluorescent core to target CD44, a receptor expressed on the cancer cell surface. Doxorubicin 85-96 CD44 molecule (Indian blood group) Homo sapiens 209-213 23529646-5 2013 To validate our hypothesis, in the first of two articles, we report the synthesis of doxorubicin (DOX)-loaded, hyaluronan (HA) coated silica nanoparticles (SNPs) containing a highly fluorescent core to target CD44, a receptor expressed on the cancer cell surface. Doxorubicin 98-101 CD44 molecule (Indian blood group) Homo sapiens 209-213 21357442-5 2011 CD44 immunohistochemistry can distinguish between tumors derived from these lines and predict tumor response to doxorubicin in vivo. Doxorubicin 112-123 CD44 molecule (Indian blood group) Homo sapiens 0-4 22309939-15 2012 Finally, whereas paclitaxel, doxorubicin, and 5-fluorouracil enriched the CD44high/CD24-/low population compared with control in SUM149, subsequent treatment with BI 2536 killed the emergent population, suggesting that it could potentially be used to prevent relapse. Doxorubicin 29-40 CD44 molecule (Indian blood group) Homo sapiens 74-78 22001557-5 2012 Addition of doxorubicin (DOX)-incorporated nanoparticles to tumor cells resulted in the expression of a strong red fluorescence color while they expressed very weak fluorescence when CD44 receptor was blocked with free HA. Doxorubicin 12-23 CD44 molecule (Indian blood group) Homo sapiens 183-187 22001557-5 2012 Addition of doxorubicin (DOX)-incorporated nanoparticles to tumor cells resulted in the expression of a strong red fluorescence color while they expressed very weak fluorescence when CD44 receptor was blocked with free HA. Doxorubicin 25-28 CD44 molecule (Indian blood group) Homo sapiens 183-187 21196304-3 2011 In the present study, we found that the CD44(+)/CD24(-/low) CSCs, isolated from both human breast cell line MCF-7 and MDA-MB-231, were more resistant to thiotepa, paclitaxel and anthracycline, when compared with the non-breast cancer stem cell subset from the same cell lines, whereas the chemosensitivities were remarkably reversed by higher concentration of thiotepa and paclitaxel except for adriamycin. Doxorubicin 395-405 CD44 molecule (Indian blood group) Homo sapiens 40-44 21792314-0 2011 Downregulation of CD44 reduces doxorubicin resistance of CD44CD24 breast cancer cells. Doxorubicin 31-42 CD44 molecule (Indian blood group) Homo sapiens 18-22 21318907-5 2011 We introduce a method using flow cytometry to assess breast CSCs (CD44(+)/CD24(-)/(low)) in human MCF-7/Dox breast cancer cells, after the treatment of mixed-backbone oligonucleotide against glucosylceramide synthase. Doxorubicin 104-107 CD44 molecule (Indian blood group) Homo sapiens 66-70 21792314-0 2011 Downregulation of CD44 reduces doxorubicin resistance of CD44CD24 breast cancer cells. Doxorubicin 31-42 CD44 molecule (Indian blood group) Homo sapiens 57-61 19772851-6 2009 Furthermore, down-regulation of P-gp1 led to increased sensitivity of CH(R)C5 cells to paclitaxel and doxorubicin, but not to cis-platinum, due to inhibition of P-gp1 drug efflux pump. Doxorubicin 102-113 CD44 molecule (Indian blood group) Homo sapiens 32-37 20211062-14 2010 CONCLUSION: A new CD44 gene variant has been found in adriamycin-resistant human breast cancer MCF-7/ADR cells. Doxorubicin 54-64 CD44 molecule (Indian blood group) Homo sapiens 18-22 19772851-6 2009 Furthermore, down-regulation of P-gp1 led to increased sensitivity of CH(R)C5 cells to paclitaxel and doxorubicin, but not to cis-platinum, due to inhibition of P-gp1 drug efflux pump. Doxorubicin 102-113 CD44 molecule (Indian blood group) Homo sapiens 161-166 19350274-7 2009 Moreover, treatment with CD44 siRNA suppresses the hyaluronan-substratum-induced doxorubicin resistance. Doxorubicin 81-92 CD44 molecule (Indian blood group) Homo sapiens 25-29 19823672-7 2009 Additionally, NSC23925 increases the intracellular accumulation of Pgp1 substrates: calcein AM, Rhodamine-123, paclitaxel, mitoxantrone, and doxorubicin. Doxorubicin 141-152 CD44 molecule (Indian blood group) Homo sapiens 67-71 34496281-7 2021 Through CD44-mediated targeting, DOX/siGCN5@HPMSNs increases drug internalization in CD44-overexpressing cancer cells, and markedly promotes DOX retention by down-regulating P-gp expression in drug-resistant cancers through silencing GCN5. Doxorubicin 33-36 CD44 molecule (Indian blood group) Homo sapiens 8-12 18828019-3 2009 METHODS: We evaluate the association between expression of Pgp1, MRP1, and BCRP proteins and ET-743 or PM00104 resistance in a large panel of multi-drug resistant cell lines derived from histologically unrelated human tumors that were selected with paclitaxel, doxorubicin, cisplatin, mitoxantrane, or gemcitibine. Doxorubicin 261-272 CD44 molecule (Indian blood group) Homo sapiens 59-63 17625788-1 2008 Hyaluronic acid (HA) coated drug carriers (HCDCs) were successfully synthesized by chemical conjugation method for targeted delivery of doxorubicin (DOX) as a prototype anticancer drug to CD44 expressed human breast cancer cell. Doxorubicin 136-147 CD44 molecule (Indian blood group) Homo sapiens 188-192 17625788-1 2008 Hyaluronic acid (HA) coated drug carriers (HCDCs) were successfully synthesized by chemical conjugation method for targeted delivery of doxorubicin (DOX) as a prototype anticancer drug to CD44 expressed human breast cancer cell. Doxorubicin 149-152 CD44 molecule (Indian blood group) Homo sapiens 188-192 34500160-5 2022 In-vitro investigations showed that the DOX-loaded polymeric micelles presented a higher intracellular release ratio in CD44-positive cells (ES2 and Hela) than in CD44-negative cells (MCF-7 and L929). Doxorubicin 40-43 CD44 molecule (Indian blood group) Homo sapiens 120-124 34500160-5 2022 In-vitro investigations showed that the DOX-loaded polymeric micelles presented a higher intracellular release ratio in CD44-positive cells (ES2 and Hela) than in CD44-negative cells (MCF-7 and L929). Doxorubicin 40-43 CD44 molecule (Indian blood group) Homo sapiens 163-167 33620265-2 2021 Taking advantage of the overexpressed CD44 receptor and mild acidic microenvironment of tumour cells, CD44-targeted pH-responsive micelles based on the self-assembly of histidine-hyaluronic acid-dodecylamine (His-HA-DA) were prepared for the delivery of doxorubicin (DOX). Doxorubicin 254-265 CD44 molecule (Indian blood group) Homo sapiens 38-42 33620265-2 2021 Taking advantage of the overexpressed CD44 receptor and mild acidic microenvironment of tumour cells, CD44-targeted pH-responsive micelles based on the self-assembly of histidine-hyaluronic acid-dodecylamine (His-HA-DA) were prepared for the delivery of doxorubicin (DOX). Doxorubicin 254-265 CD44 molecule (Indian blood group) Homo sapiens 102-106 33620265-2 2021 Taking advantage of the overexpressed CD44 receptor and mild acidic microenvironment of tumour cells, CD44-targeted pH-responsive micelles based on the self-assembly of histidine-hyaluronic acid-dodecylamine (His-HA-DA) were prepared for the delivery of doxorubicin (DOX). Doxorubicin 267-270 CD44 molecule (Indian blood group) Homo sapiens 38-42 33620265-2 2021 Taking advantage of the overexpressed CD44 receptor and mild acidic microenvironment of tumour cells, CD44-targeted pH-responsive micelles based on the self-assembly of histidine-hyaluronic acid-dodecylamine (His-HA-DA) were prepared for the delivery of doxorubicin (DOX). Doxorubicin 267-270 CD44 molecule (Indian blood group) Homo sapiens 102-106 33620265-4 2021 Compared with free DOX, DOX/HHD exhibited relatively high cellular uptake mainly via the CD44-mediated endocytosis. Doxorubicin 19-22 CD44 molecule (Indian blood group) Homo sapiens 89-93 33620265-4 2021 Compared with free DOX, DOX/HHD exhibited relatively high cellular uptake mainly via the CD44-mediated endocytosis. Doxorubicin 24-27 CD44 molecule (Indian blood group) Homo sapiens 89-93 18259754-10 2008 CD44 ASO also increased chemosensitivity to doxorubicin significantly, lowered IC(50 )by one order of magnitude. Doxorubicin 44-55 CD44 molecule (Indian blood group) Homo sapiens 0-4 18259754-11 2008 Apoptosis and necrosis were also induced by CD44 ASO alone or in combination treatment with doxorubicin. Doxorubicin 92-103 CD44 molecule (Indian blood group) Homo sapiens 44-48 18441325-6 2008 Furthermore, we observed that HA-CD44 interaction induces ankyrin (a cytoskeletal protein) binding to MDR1 resulting in the efflux of chemotherapeutic drugs (e.g. doxorubicin and paclitaxel (Taxol)) and chemoresistance in these tumor cells. Doxorubicin 163-174 CD44 molecule (Indian blood group) Homo sapiens 33-37 33773562-17 2021 Phospho-Akt, NFkappaB consequentially decreased doxorubicin accumulation by enhancing the expressions of ABCG2 and Pgp1 respectively. Doxorubicin 48-59 CD44 molecule (Indian blood group) Homo sapiens 115-119 33620265-0 2021 CD44-targeted pH-responsive micelles for enhanced cellular internalization and intracellular on-demand release of doxorubicin. Doxorubicin 114-125 CD44 molecule (Indian blood group) Homo sapiens 0-4 34496281-7 2021 Through CD44-mediated targeting, DOX/siGCN5@HPMSNs increases drug internalization in CD44-overexpressing cancer cells, and markedly promotes DOX retention by down-regulating P-gp expression in drug-resistant cancers through silencing GCN5. Doxorubicin 33-36 CD44 molecule (Indian blood group) Homo sapiens 85-89 34496281-7 2021 Through CD44-mediated targeting, DOX/siGCN5@HPMSNs increases drug internalization in CD44-overexpressing cancer cells, and markedly promotes DOX retention by down-regulating P-gp expression in drug-resistant cancers through silencing GCN5. Doxorubicin 141-144 CD44 molecule (Indian blood group) Homo sapiens 8-12 34496281-7 2021 Through CD44-mediated targeting, DOX/siGCN5@HPMSNs increases drug internalization in CD44-overexpressing cancer cells, and markedly promotes DOX retention by down-regulating P-gp expression in drug-resistant cancers through silencing GCN5. Doxorubicin 141-144 CD44 molecule (Indian blood group) Homo sapiens 85-89 34496281-11 2021 This nanosystem efficiently co-delivered DOX and siGCN5 into drug-resistant cancer cells and significantly inhibited the tumor growth through: (1) HA shell enhanced the cellular internalization of loaded DOX and siGCN5 via CD44-mediated targeting; (2) the pH/redox dual-responsive nanosystem released the cargos in response to the intracellular environment; (3) the released siGCN5 downregulated P-gp epigenetically. Doxorubicin 41-44 CD44 molecule (Indian blood group) Homo sapiens 223-227 34496281-11 2021 This nanosystem efficiently co-delivered DOX and siGCN5 into drug-resistant cancer cells and significantly inhibited the tumor growth through: (1) HA shell enhanced the cellular internalization of loaded DOX and siGCN5 via CD44-mediated targeting; (2) the pH/redox dual-responsive nanosystem released the cargos in response to the intracellular environment; (3) the released siGCN5 downregulated P-gp epigenetically. Doxorubicin 204-207 CD44 molecule (Indian blood group) Homo sapiens 223-227 34200716-3 2021 Importantly, the DOX@aHA-DMA/Fe NPs improved tumor cellular uptake due to HA-mediated endocytosis for tumor cells overexpressing CD44 receptors. Doxorubicin 17-20 CD44 molecule (Indian blood group) Homo sapiens 129-133 34592836-0 2021 Targeted delivery of doxorubicin through CD44 aptamer to cancer cells. Doxorubicin 21-32 CD44 molecule (Indian blood group) Homo sapiens 41-45 34592836-1 2021 Aim: The current investigation is focused on the targeted delivery of doxorubicin through CD44-aptamer-mediated active targeting to the human breast cancer cells. Doxorubicin 70-81 CD44 molecule (Indian blood group) Homo sapiens 90-94 34592836-2 2021 Methods: CD44-aptamer-doxorubicin (Apt-Dox) conjugates were developed by incubating different molar ratios of aptamer and doxorubicin. Doxorubicin 22-33 CD44 molecule (Indian blood group) Homo sapiens 9-13 34592836-2 2021 Methods: CD44-aptamer-doxorubicin (Apt-Dox) conjugates were developed by incubating different molar ratios of aptamer and doxorubicin. Doxorubicin 39-42 CD44 molecule (Indian blood group) Homo sapiens 9-13 34592836-2 2021 Methods: CD44-aptamer-doxorubicin (Apt-Dox) conjugates were developed by incubating different molar ratios of aptamer and doxorubicin. Doxorubicin 122-133 CD44 molecule (Indian blood group) Homo sapiens 9-13 34592836-6 2021 Apt-Dox conjugate selectively internalized and accumulated in CD44-overexpressing cells. Doxorubicin 4-7 CD44 molecule (Indian blood group) Homo sapiens 62-66 34592836-7 2021 Conclusion: Apt-Dox conjugate selectively delivers doxorubicin to CD44-expressing cancer cells, thereby inhibiting selective cell proliferation and enhancing the targeted therapy. Doxorubicin 16-19 CD44 molecule (Indian blood group) Homo sapiens 66-70 34592836-7 2021 Conclusion: Apt-Dox conjugate selectively delivers doxorubicin to CD44-expressing cancer cells, thereby inhibiting selective cell proliferation and enhancing the targeted therapy. Doxorubicin 51-62 CD44 molecule (Indian blood group) Homo sapiens 66-70 34200614-8 2021 In addition, genes known to be associated with drug resistance, such as SOX2, OCT4, and CD44 are overexpressed in heterotypic tumorspheres post-chemotherapy, indicating that the duo collectively repels the effect of doxorubicin. Doxorubicin 216-227 CD44 molecule (Indian blood group) Homo sapiens 88-92 34200716-4 2021 As a result, the average fluorescent DOX intensity observed in MDA-MB-231 cells (with CD44 receptors) was ~7.9 x 102 (DOX@HA/Fe NPs, without DMA), ~8.1 x 102 (DOX@aHA-DMA0.36/Fe NPs), and ~9.3 x 102 (DOX@aHA-DMA0.60/Fe NPs). Doxorubicin 37-40 CD44 molecule (Indian blood group) Homo sapiens 86-90 34200716-4 2021 As a result, the average fluorescent DOX intensity observed in MDA-MB-231 cells (with CD44 receptors) was ~7.9 x 102 (DOX@HA/Fe NPs, without DMA), ~8.1 x 102 (DOX@aHA-DMA0.36/Fe NPs), and ~9.3 x 102 (DOX@aHA-DMA0.60/Fe NPs). Doxorubicin 118-121 CD44 molecule (Indian blood group) Homo sapiens 86-90 35501796-5 2022 Due to the high expression of CD44 receptor on the surface of tumor cells, we encapsulated chondroitin sulfate gel shell (CS-shell) with CD44 targeting and apoptosis promoting effect on the surface of DOX@MOF-COD nanoparticles, which can accurately and efficiently deliver the drugs to the tumor site and improve the effect of reversing drug resistance. Doxorubicin 201-204 CD44 molecule (Indian blood group) Homo sapiens 30-34 35501796-5 2022 Due to the high expression of CD44 receptor on the surface of tumor cells, we encapsulated chondroitin sulfate gel shell (CS-shell) with CD44 targeting and apoptosis promoting effect on the surface of DOX@MOF-COD nanoparticles, which can accurately and efficiently deliver the drugs to the tumor site and improve the effect of reversing drug resistance. Doxorubicin 201-204 CD44 molecule (Indian blood group) Homo sapiens 137-141 35184000-6 2022 Furthermore, the outer layer hyaluronic acid can load doxorubicin and target overexpressed receptor CD44 of cancer cell, meanwhile, trigger release of DOX in photothermal condition and acidic tumor microenvironment. Doxorubicin 151-154 CD44 molecule (Indian blood group) Homo sapiens 100-104 35277914-5 2022 This active targeting, mediated by CD44-HA interaction, allows DOX and EPS to be delivered simultaneously to tumor cells in vivo, where they suppress not only TNBC tumor growth and the epithelial-mesenchymal transition, but also cancer stem cells, which collectively suppress tumor growth and metastasis of TNBC and may also act to prevent relapse of TNBC. Doxorubicin 63-66 CD44 molecule (Indian blood group) Homo sapiens 35-39 35216501-1 2022 In this study, actively-targeted (CD44-receptors) and dual stimuli (pH/redox)-responsive lipid-polymer nanoparticles were proposed as a delivery vehicle of doxorubicin hydrochloride in triple negative breast cancer cell lines. Doxorubicin 156-181 CD44 molecule (Indian blood group) Homo sapiens 34-38 35484752-2 2022 In this study, we developed high-efficiency nanotheranostic agent based on ferroferric oxide, manganese dioxide, hyaluronic acid and doxorubicin (FMDH-D NPs) for dual targeting and imaging guided synergetic photothermal-enhanced chemodynamic/chemotherapy for cancer, which improved the specific uptake of drugs at tumor site by the dual action of CD44 ligand hyaluronic acid and magnetic nanoparticles guided by magnetic force. Doxorubicin 133-144 CD44 molecule (Indian blood group) Homo sapiens 347-351